UCB S.A. UNSP.ADR 1/2 (UNC0) - Total Liabilities
Based on the latest financial reports, UCB S.A. UNSP.ADR 1/2 (UNC0) has total liabilities worth €8.98 Billion EUR (≈ $10.50 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check UCB S.A. UNSP.ADR 1/2 (UNC0) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
UCB S.A. UNSP.ADR 1/2 - Total Liabilities Trend (2021–2025)
This chart illustrates how UCB S.A. UNSP.ADR 1/2's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of UCB S.A. UNSP.ADR 1/2.
UCB S.A. UNSP.ADR 1/2 Competitors by Total Liabilities
The table below lists competitors of UCB S.A. UNSP.ADR 1/2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
USA | $12.04 Billion |
|
Commerzbank AG
F:ZZMS
|
Germany | €583.62 Billion |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
USA | $33.64 Billion |
|
Sun Life Financial Inc.
TO:SLF
|
Canada | CA$372.96 Billion |
|
Thomson Reuters Corp
TO:TRI
|
Canada | CA$6.95 Billion |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
China | CN¥9.46 Trillion |
|
Fifth Third Bancorp
NASDAQ:FITB
|
USA | $262.93 Billion |
|
Itau Unibanco Banco Holding SA
NYSE:ITUB
|
USA | $2.92 Trillion |
Liability Composition Analysis (2021–2025)
This chart breaks down UCB S.A. UNSP.ADR 1/2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See UNC0 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UCB S.A. UNSP.ADR 1/2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UCB S.A. UNSP.ADR 1/2 (2021–2025)
The table below shows the annual total liabilities of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.29 Billion ≈ $8.52 Billion |
-0.37% |
| 2024-12-31 | €7.32 Billion ≈ $8.56 Billion |
+11.49% |
| 2023-12-31 | €6.56 Billion ≈ $7.67 Billion |
-3.53% |
| 2022-12-31 | €6.80 Billion ≈ $7.95 Billion |
+16.83% |
| 2021-12-31 | €5.82 Billion ≈ $6.81 Billion |
-- |
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more